financetom
Business
financetom
/
Business
/
Pentair beats Q3 estimates on strong industrial and pool demand
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Pentair beats Q3 estimates on strong industrial and pool demand
Oct 21, 2025 5:10 AM

Oct 21 (Reuters) - UK-based water technology company

Pentair ( PNR ) reported better-than-expected quarterly profit

and revenue on Tuesday, as sales growth in industrial

technologies and pool segments offset declines in the water

solutions segment.

The London, UK-based company posted third-quarter revenue of

$1.02 billion, slightly above analysts' estimates of $1.01

billion, according to data complied by LSEG.

Net income rose to $184.3 million, or $1.12 per share, for

the quarter ended September 30, from $139.6 million, or 84 cents

per share, a year earlier.

On an adjusted basis, the company reported a profit of $1.24

per share, above estimates of $1.18 per share.

Pentair ( PNR ) manufactures filtration systems for residential and

industrial use across 150 countries, along with water pumps for

flood control, fire suppression and homes. It also produces

heating systems, pumps, and LED lighting for swimming pools.

The company raised its full-year adjusted earnings forecast

to a range of $4.85-$4.90 per share, representing about 13%

growth from last year.

Pentair ( PNR ) also announced that finance chief Bob Fishman will

step down effective March 1, after six years in the role. He

will be succeeded by Nick Brazi, currently vice president of

corporate development.

U.S. listed shares of the company were up 2.5% to $111.99

before markets open.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Update: Market Chatter: China's Cnooc Files Arbitration Claim to Establish Right Over Hess Ownership in Stabroek Oilfield
Update: Market Chatter: China's Cnooc Files Arbitration Claim to Establish Right Over Hess Ownership in Stabroek Oilfield
Mar 22, 2024
03:31 PM EDT, 03/22/2024 (MT Newswires) -- (Updates with comments from Hess and Chevron ( CVX ) in the second- and- third-to-last paragraphs.) China's Cnooc has filed an arbitration claim against Hess (HES), following Exxon Mobil ( XOM ) in trying to establish a right over the company's stake in the Stabroek oilfield in Guyana, Reuters reported Friday. We have...
Ocugen Stock Rallies After Appeals Court Dismisses Allegations of Misleading Shareholders
Ocugen Stock Rallies After Appeals Court Dismisses Allegations of Misleading Shareholders
Mar 22, 2024
03:37 PM EDT, 03/22/2024 (MT Newswires) -- Ocugen ( OCGN ) shares surged nearly 19% Friday, a day after a federal appeals court upheld a lower-court decision, dismissing allegations of misleading shareholders with its statements about a prospective COVID-19 vaccine and its approvals in the US. Plaintiffs alleged that Ocugen ( OCGN ) made statements suggesting the US Food and...
First Citizens Bancshares Insider Sold Shares Worth $4,665,006, According to a Recent SEC Filing
First Citizens Bancshares Insider Sold Shares Worth $4,665,006, According to a Recent SEC Filing
Mar 22, 2024
03:27 PM EDT, 03/22/2024 (MT Newswires) -- Ellen R Alemany, Director, on March 20, 2024, sold 3,000 shares in First Citizens Bancshares (FCNCA) for $4,665,006. Following the Form 4 filing with the SEC, Alemany has control over a total of 52,478 shares of the company, with 34,842 shares held directly and 17,636 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/798941/000095017024035295/xslF345X03/ownership.xml Price: 1587.40, Change:...
AbbVie Gets US FDA's Full Approval for Ovarian Cancer Treatment
AbbVie Gets US FDA's Full Approval for Ovarian Cancer Treatment
Mar 22, 2024
03:31 PM EDT, 03/22/2024 (MT Newswires) -- AbbVie ( ABBV ) said Friday it got full approval from the US Food and Drug Administration for Elahere, or mirvetuximab soravtansine-gynx, for the treatment of certain ovarian cancer patients. The health's regulator approval was based on the results of the phase 3 Mirasol trial in patients with epithelial ovarian, fallopian tube or...
Copyright 2023-2026 - www.financetom.com All Rights Reserved